The anti-PD-L1 mAb durvalumab was compared to investigator’s choice standard chemotherapy in the randomized phase III EAGLE trial including 736 patients with R/M HNSCC and did not improve survival as a single agent or in combination with the CTLA-4 inhibitor, tremelimumab. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.